CN105273027A - Cangrelor intermediate and preparation method and application thereof - Google Patents
Cangrelor intermediate and preparation method and application thereof Download PDFInfo
- Publication number
- CN105273027A CN105273027A CN201410350976.1A CN201410350976A CN105273027A CN 105273027 A CN105273027 A CN 105273027A CN 201410350976 A CN201410350976 A CN 201410350976A CN 105273027 A CN105273027 A CN 105273027A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- preparation
- cangrelor
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of preparation method of cangrelor. The invention discloses a new intermediate compound 3 for preparing cangrelor. The invention discloses the new intermediate compound 3 for preparing cangrelor and a preparation method thereof. By changing an N- protection group, and adopting weaker-activity formyl as an N protection group, the new N-formyl protective intermediate 3 is obtained successfully; the intermediate has the advantages of high purity, good stability, easy operation of preparation method and the like. The difficulties in the prior art that the yield is low and the product is difficult to purify and separate are solved.
Description
Technical field
The present invention relates to cangrelor preparation method technical field.
Background technology
Cangrelor, English name: cangrelor, chemical name: N-[2-(methylthio group) ethyl]-2-[(3,3,3-trifluoro propyl) sulfo-]-5'-AMP, single acid anhydride of band dichloromethylene bisphosphate, tetra-na salt, chemical structural formula:
Pharmaceuticals of cangrelor system TheMedicinesCompany develops, and is in the clinical experiment of III phase at present, belongs to platelet ADP (P
2y
12) antiplatelet drug of receptor antagonist class.
About the synthesis of cangrelor; at patent CN1042430C and paper J.Med.Chem.1999; 42; have in 213-220 and specially state; all these documents employ N-ethanoyl-2-[(3,3,3-trifluoro propyl) sulfo-] adenosine-2' bar none; 3', 5'-triethyl (following formula 6 compound) is as the key intermediate of in synthetic route.With J.Med.Chem.1999; 42; 213-220 is example; 2-[(3; 3; 3-trifluoro propyl) sulfo-] adenosine (1) is starting raw material, generates the compound N-acetyl-2-[(3,3 of four acetyl protections with acetic anhydride; 3-trifluoro propyl) sulfo-] adenosine-2'; 3', 5'-triethyl (6), then compound 6 nucleo philic substitution reaction; basic hydrolysis deacetylation; obtain cangrelor key intermediate (5), then obtain cangrelor through phosphorylated, shown in 1-2.
Analyze existing N-ethanoyl-2-[(3; 3; 3-trifluoro propyl) sulfo-] adenosine-2', the synthetic route of 3', 5'-triethyl (6) is known; in actual acylation process;, 2-[(3,3; 3-trifluoro propyl) sulfo-] in adenosine (1) and acetic anhydride, four pure acetylizad target products can not be obtained.Tracing it to its cause is that the activity of 2-[(3,3,3-trifluoro propyl) sulfo-] adenosine 6 nitrogen-atoms is comparatively strong, N easily produces the by product of diacetylation in acetylation, is shown below.The generation of this by product causes purifying products difficulty, progressively bring subsequently product into.
Summary of the invention
Object of the present invention is exactly the problems referred to above overcoming prior art existence, provides a kind of intermediate preparing cangrelor newly.Utilize the intermediate that this is new, can simple high yield obtain cangrelor.
Another object of the present invention is to provide the preparation method and application of described new intermediate.
For reaching above-mentioned purpose, technical scheme of the present invention is as follows:
The compound 3 of following formula:
Compound 3, its chemical name is N-formyl radical-N-[2-(methylthio group) ethyl]-2-[(3,3,3-trifluoro propyl) sulfo-] adenosine-2', 3', 5'-triethyl.
The preparation method of formula 3 compound, the method is down to room temperature after formic acid is added diacetyl oxide, adds compound 2 and be obtained by reacting
The preparation of above-mentioned formula 3 compound, preferred condition after 40-60 DEG C of reaction 20-40min, is down to room temperature after formic acid is added diacetyl oxide.Add the temperature of reaction after compound 2 generally at 60-100 DEG C.Compound 2 is preferably 1:4-1:50 with the molar ratio of formic acid, and compound 2 is preferably 1:4-:1:10 with the molar ratio of diacetyl oxide.
Further, formula 2 compound 2-[(3,3,3-trifluoro propyl) sulfo-] adenosine is dissolved in diacetyl oxide to add acid binding agent and be obtained by reacting:
The preparation method of above-mentioned formula 2 compound, during reaction, temperature is-15 DEG C-40 DEG C, preferably-5 DEG C-20 DEG C.Described acid binding agent can be sodium acetate, pyridine, triethylamine etc., preferred pyridine.Compound 1 is preferably 1:5-1:50 with the molar ratio of diacetyl oxide.
Formula 3 compound is for the preparation of cangrelor and other known intermediate, and yield and purity are all much improved than prior art.
Formula 3 compound is as follows for the preparation of the step of cangrelor and other known intermediate:
1) compound 3 is dissolved in reaction solvent, adds 2-chloroethyl Dimethyl sulfide under alkaline condition and be obtained by reacting compound 4
2) compound 4 is hydrolyzed in the basic conditions obtains compound 5
The preparation method of above-mentioned formula 4 compound, described alkaline condition can be mineral alkali salt of wormwood, sodium carbonate etc., or organic bases triethylamine, pyridine etc.; Preferred salt of wormwood or sodium carbonate.
Midbody compound 5 prepares the method for cangrelor can with reference to prior art.
Beneficial effect of the present invention: the major cause that prior art products obtained therefrom purity is not high be adenosine N on two hydrogen atoms have quite active; to be easy to replace by ethanoyl; and two hydrogen atoms do not have selectivity; easily go up two protecting groups simultaneously; cause yield low, product is difficult to the difficulty of purifies and separates.Applicant of the present invention, by changing N-protected base, adopts active more weak formyl radical as N protecting group, obtains the intermediate of a kind of new N-formyl radical protection smoothly, the advantages such as it is high that this intermediate has purity, good stability, preparation method's easy handling.
Embodiment
Below in conjunction with embodiment, the present invention is described in further detail, but does not therefore limit the present invention among described scope of embodiments.
Experiment material involved in following content and reagent are then commercially available product if not otherwise specified.Reaction scheme from existing raw material to obtained midbody compound 5 is as follows:
Embodiment 1-4:2-[(3,3,3-trifluoro propyl) sulfo-] adenosine-2', the synthesis of 3', 5'-triethyl (2)
By 2-[(3,3,3-trifluoro propyl) sulfo-] adenosine (10.0g, 25.3mmol) is dissolved in pyridine (20ml, 253mmol, 10eq), under ice bath, drip diacetyl oxide (35ml, 5eq),-5 DEG C of reaction 3h, add 100ml elutriation and go out white solid, stir 1h suction filtration and obtain white solid 11.35g, yield 86%.ESI-MS(m/z)：522.13[M+H]
+，544.11[M+Na]
+，560.09[M+K]
+；1HNMRδ(CDCl
3)7.87(1H，s，H-8)，6.14(1H，d，H-1')，5.82(1H，t，H-2')，5.67(2H，s，NH
2)，5.45(1H，m，H-3')，4.41(3H，m，H-4',5'),3.29(2H，m，SCH
2),2.63(2H，m，CF
3CH
2)，2.13(3H，s，CH
3CO)，2.12(3H，s，CH
3CO),2.07(3H，s，CH
3CO)。
By 2-[(3,3,3-trifluoro propyl) sulfo-] adenosine (5.0g, 12.65mmol) is dissolved in diacetyl oxide (60ml, 632.34mmol, be down to-15 DEG C 50eq), add triethylamine (3.84g, 3eq), reaction 7h, add 50ml elutriation and go out white solid, stir 1h suction filtration and obtain white solid 3.94g, yield 60%.
By 2-[(3,3,3-trifluoro propyl) sulfo-] adenosine (10.0g, 25.3mmol) be dissolved in pyridine (26ml, 324mmol, 13eq) in, drip diacetyl oxide (40ml under ice bath, 426mmol, 17eq), 10 DEG C of reaction 3h, add 100ml elutriation and go out white solid, stir 1h suction filtration and obtain white solid 11.35g, yield 86%.
By 2-[(3,3,3-trifluoro propyl) sulfo-] adenosine (5.0g, 12.65mmol) and sodium acetate (0.62g, 7.59mmol, 0.6eq) be dissolved in diacetyl oxide (6ml, 63.2mmol, 5eq) in 40 DEG C reaction 5h, add 10ml elutriation and go out white solid, stir 1h suction filtration and obtain white solid 4.48g, yield 68%.
Embodiment 5-8N-formyl radical-2-[(3,3,3-trifluoro propyl) sulfo-] adenosine-2', the synthesis of 3', 5'-triacetyl (3)
Stir 30min at formic acid (13ml, 345mmol, 18eq) being added diacetyl oxide (27ml, 288mmol, 15eq) 50 DEG C under low temperature, be down to room temperature, add compound 2 (10.0g, 19.2mmol), 70 DEG C of reaction 3.5h.The 65ml that adds water separates out white solid, and about 20 DEG C are stirred 2h suction filtration and obtain compound (3) (9.86g, yield 94.0%).ESI-MS(m/z)：572.15[M+Na]
+；1HNMRδ(CDCl
3)9.83(2H，s，NH+CHO)，8.40(1H，s，H-8)，6.21(1H，d，H-1')，5.85(1H，t，H-2')，5.56(1H，t，H-3')，4.40(3H，4-H'+5-2H')，3.32(2H，SCH
2)，2.64(2H，CF
3-CH
2)，2.15-2.07(6H，CH
3CO)。
Under low temperature, formic acid (14.47ml, 383.5mmol, 50eq) is added diacetyl oxide (7.25ml, 76.7mmol, 10eq) stir 30min at 50 DEG C, be down to 25 DEG C, add compound 2 (4.0g, 7.67mmol), 60 DEG C of reaction 10h.The 65ml that adds water separates out white solid, and about 20 DEG C are stirred 2h suction filtration and obtain compound (3) (3.50g, yield 83%).
Stir 30min at formic acid (13ml, 345mmol, 18eq) being added diacetyl oxide (27ml, 288mmol, 15eq) 50 DEG C under low temperature, be down to room temperature, add compound 2 (10.0g, 19.2mmol), 80 DEG C of reaction 3.5h.The 65ml that adds water separates out white solid, and about 20 DEG C are stirred 2h suction filtration and obtain compound (3) (9.86g, yield 94.0%)
Stir 30min at formic acid (1.74ml, 46.0mmol, 4eq) being added diacetyl oxide (4.35ml, 46.0mmol, 4eq) 50 DEG C under low temperature, be down to 25 DEG C, add compound 2 (6.0g, 11.5mmol), 100 DEG C of reaction 2h.The 65ml that adds water separates out white solid, and about 20 DEG C are stirred 2h suction filtration and obtain compound (3) (5.06g, yield 80%)
Embodiment 9-12:N-formyl radical-N-[2-(methylthio group) ethyl]-2-[(3,3,3-trifluoro propyl) sulfo-] adenosine-2', the synthesis of 3', 5'-triacetyl (4)
Compound 3 (8.0g, 14.6mmol) is dissolved in 80mlDMF, then adds salt of wormwood (4.02g, 2eq), 60 DEG C of reaction 1h, add 2-chloroethyl Dimethyl sulfide (4.35ml, 3eq) 60 DEG C of reaction 2h, obtain dark syrup thing 8.58g, yield 94%.TLC (methylene dichloride: methyl alcohol=20:1) R
f=0.9.
Compound 3 (5.0g, 9.1mmol) is dissolved in 50mlDMF, then adds triethylamine (1.3ml, 1eq), 60 DEG C of reaction 1h, add 2-chloroethyl Dimethyl sulfide (1.81ml, 2eq) 25 DEG C of reaction 15h, obtain dark syrup thing 3.42g, yield 60%.
Compound 3 (4.0g, 7.3mmol) is dissolved in 40mlDMF, then adds sodium carbonate (1.54g, 2eq), 60 DEG C of reaction 1h, add 2-chloroethyl Dimethyl sulfide (2.2ml, 3eq) 60 DEG C of reaction 2h, obtain dark syrup thing 4.34g, yield 95%.
Compound 3 (4.0g, 7.3mmol) is dissolved in 40mlDMF, then adds sodium acetate (1.19g, 2eq), 60 DEG C of reaction 1h, add 2-chloroethyl Dimethyl sulfide (2.2ml, 3eq) 100 DEG C of reaction 1h, obtain dark syrup thing 3.50g, yield 80%.
Embodiment 13:N-[2-(methylthio group) ethyl]-2-[(3,3,3-trifluoro propyl) sulfo-] adenosine (5) synthesizes
Be dissolved in by compound 4 (2.57g, 4.1mmol) in methyl alcohol (80ml) solution of sodium hydroxide (2.14g, 53.6mmol, 13eq), backflow 1h, decompression evaporates methyl alcohol, adds water, and separates out white solid 1.72g, yield 89%.
ESI-MS(m/z)：624[M+H]
+，646[M+Na，]
+；
1HNMR(DMSO-d
6,400MHz)δ：8.25(1H，s，H-8)，8.02(1H，s，NH)，5.82(1H，d)，5.36(1H，s，OH)，5.11(1H，s，OH),5.00(1H，s，OH),4.56(1H),4.13(2H)，3.92(1H，m)，3.63，(4H)，3.27(2H)，2.72(4H)，2.06(3H,s,SCH
3)。
Claims (10)
1. the compound 3 of following formula:
2. the preparation method of formula 3 compound, the method is down to room temperature after formic acid is added diacetyl oxide, adds compound 2 and be obtained by reacting
3. the preparation of formula 3 compound as claimed in claim 2, is characterized in that: after 40-60 DEG C of reaction 20-40min, be down to room temperature after formic acid being added diacetyl oxide.
4. the preparation of formula 3 compound as claimed in claim 2, it is characterized in that: compound 2 is 1:4-1:50 with the mol ratio of formic acid, compound 2 is 1:4-:1:10 with the mol ratio of diacetyl oxide.
5. the preparation of formula 3 compound as claimed in claim 2, is characterized in that: formula 2 compound 2-[(3,3,3-trifluoro propyl) sulfo-] adenosine is dissolved in diacetyl oxide to add acid binding agent and be obtained by reacting:
6. the preparation of formula 3 compound as claimed in claim 5, is characterized in that: during reaction, temperature is-5 DEG C-20 DEG C.
7. the application of formula 3 compound when preparing cangrelor.
8. the application of formula 3 compound when preparing cangrelor as claimed in claim 7, is characterized in that comprising the steps:
1) compound 3 is dissolved in reaction solvent, adds 2-chloroethyl Dimethyl sulfide under alkaline condition and be obtained by reacting compound 4
2) compound 4 is hydrolyzed in the basic conditions obtains compound 5
9. the application of formula 3 compound when preparing cangrelor as claimed in claim 8, is characterized in that the alkali that preparation formula 4 compound uses is mineral alkali salt of wormwood, sodium carbonate, triethylamine or pyridine.
10. the application of formula 3 compound when preparing cangrelor as claimed in claim 9, is characterized in that the alkali that preparation formula 4 compound uses is salt of wormwood or sodium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410350976.1A CN105273027B (en) | 2014-07-22 | 2014-07-22 | Cangrelor intermediate and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410350976.1A CN105273027B (en) | 2014-07-22 | 2014-07-22 | Cangrelor intermediate and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105273027A true CN105273027A (en) | 2016-01-27 |
| CN105273027B CN105273027B (en) | 2018-11-06 |
Family
ID=55142920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410350976.1A Active CN105273027B (en) | 2014-07-22 | 2014-07-22 | Cangrelor intermediate and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105273027B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105949258A (en) * | 2016-05-06 | 2016-09-21 | 浙江永宁药业股份有限公司 | Synthesis method of cangrelor intermediate |
| CN107973832A (en) * | 2016-10-25 | 2018-05-01 | 上海医药工业研究院 | The preparation method of 6-N- [2- (methyl mercapto) ethyl] -2- [(3,3,3- trifluoro propyls) is thio] adenosine |
| CN109912673A (en) * | 2017-12-12 | 2019-06-21 | 亚宝药业集团股份有限公司 | Cangrelor intermediate and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014832A1 (en) * | 1992-12-23 | 1994-07-07 | Novo Nordisk A/S | Purine derivatives |
| CN1466591A (en) * | 2000-08-30 | 2004-01-07 | - | Nucleoside derivatives |
| WO2012100654A1 (en) * | 2011-01-26 | 2012-08-02 | 北京化工大学 | Ribofuranosyl purine compound, preparation method therefor, and use thereof |
-
2014
- 2014-07-22 CN CN201410350976.1A patent/CN105273027B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014832A1 (en) * | 1992-12-23 | 1994-07-07 | Novo Nordisk A/S | Purine derivatives |
| CN1466591A (en) * | 2000-08-30 | 2004-01-07 | - | Nucleoside derivatives |
| WO2012100654A1 (en) * | 2011-01-26 | 2012-08-02 | 北京化工大学 | Ribofuranosyl purine compound, preparation method therefor, and use thereof |
Non-Patent Citations (3)
| Title |
|---|
| ANTHONY H. INGALL，等: "Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic Therapy", 《J. MED. CHEM.》 * |
| ASHOK C. BAJJI，等: "Synthesis of the tRNALys,3 Anticodon Stem-Loop Domain Containing the Hypermodified ms2t6A Nucleoside", 《J. ORG. CHEM.》 * |
| 华东理工大学有机化学教研组: "《有机合成中的保护基》", 31 October 2004 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105949258A (en) * | 2016-05-06 | 2016-09-21 | 浙江永宁药业股份有限公司 | Synthesis method of cangrelor intermediate |
| CN105949258B (en) * | 2016-05-06 | 2019-05-31 | 浙江永宁药业股份有限公司 | A kind of synthetic method of cangrelor intermediate |
| CN107973832A (en) * | 2016-10-25 | 2018-05-01 | 上海医药工业研究院 | The preparation method of 6-N- [2- (methyl mercapto) ethyl] -2- [(3,3,3- trifluoro propyls) is thio] adenosine |
| CN109912673A (en) * | 2017-12-12 | 2019-06-21 | 亚宝药业集团股份有限公司 | Cangrelor intermediate and preparation method thereof |
| CN109912673B (en) * | 2017-12-12 | 2022-01-25 | 亚宝药业集团股份有限公司 | Cangrelor intermediate and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105273027B (en) | 2018-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105273025A (en) | Intermediate for preparing cangrelor and preparation method and application thereof | |
| CN105273026A (en) | Drug intermediate and preparation method and application thereof | |
| US9840466B2 (en) | Process of making adamantanamides | |
| US8193354B2 (en) | Process for preparation of Gemcitabine hydrochloride | |
| CN104356109B (en) | A kind of preparation method of 2-((4R, 6S)-6-bromomethyl-2,2-dimethyl-1,3-dioxane-4-base) acetic acid esters | |
| CN105452256A (en) | Method for preparing a pyripyropene compound | |
| CN105273027A (en) | Cangrelor intermediate and preparation method and application thereof | |
| CN102395591A (en) | Method for preparing prasugrel | |
| CN101302207B (en) | Preparation of 3-o-alkyl-5,6-o-(1-methyl ethylidine)-l-ascorbic acid and preparation of 5,6-o-(1- methyl ethylidine)-l- ascorbic acid | |
| CN104402909A (en) | Synthetic method of cefoxitin acid | |
| KR101119027B1 (en) | Method for preparating ascorbic acid derivatives | |
| CN106279207A (en) | A kind of synthetic method of cefdinir | |
| CN104961787B (en) | Synthetic method of cordycepin | |
| JP2015508084A (en) | Method for producing 3-O-benzyl-1,2-O-isopropylidene-α-L-idfuranose | |
| CN104744537A (en) | Synthetic method of capecitabine | |
| CN105085595B (en) | A kind of method of deacylation base protection 2,6 halosubstituted purine nucleosides of synthesis | |
| CN104910209B (en) | A kind of method for preparing tenofovir | |
| CN104059057A (en) | Preparation method of lamivudine impurity 3-TU | |
| CN107235853A (en) | It is a kind of to be used to prepare Canton love-pea vine A prime and its synthetic method of isomers | |
| CN103265470A (en) | Synthetic method of silodosin dialkylate | |
| PL111162B1 (en) | Method of producing s-triethylophosphinogold 2,3,4,6-tetra-o-acetylo-beta-d-glycopyranosylothiol-1-ane | |
| CN102875344B (en) | A kind of preparation method of 2,3,4-TMB | |
| CN109422797B (en) | Preparation method of lisinopril intermediate | |
| CN109761911A (en) | A kind of preparation method of the polysubstituted pyrimidine derivative as Elagolix intermediate | |
| CN105037348B (en) | A kind of Retapamulin synthetic method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Qingrong Inventor after: Wang Hubo Inventor after: Zhu Xueyan Inventor after: Yuan Zhedong Inventor after: Zhang Xiquan Inventor after: Wang Shanchun Inventor before: Wang Qingrong Inventor before: Wang Hubo Inventor before: Zhu Xueyan Inventor before: Yuan Zhedong |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160412 Address after: 200040 Beijing West Road, Shanghai, No. 1320, No. Applicant after: Shanghai Institute of pharmaceutical industry Applicant after: China State Institute of Pharmaceutical Industry Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 200040 Beijing West Road, Shanghai, No. 1320, No. Applicant before: Shanghai Institute of pharmaceutical industry Applicant before: China State Institute of Pharmaceutical Industry |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |